ACS经皮冠状动脉介入治疗后P2Y12受体抑制剂应用策略  

Application strategy of P2Y12 receptor inhibitors in patients with acute coronary syndrome after percutaneous coronary intervention

作　　者：王朝晖[1] 苏冠华[2] WANG Zhaohui;SUGuanhua(Institution of Geriatric Medicine,Union Hospital,Tongji Medical College,Huazhong Universi ty of Science and Technology,Wuhan,430022,China;Department of Cardiology,Union Hospi tal,Tongji Medical College,Huazhong University of Science and Technology)

机构地区：[1]华中科技大学同济医学院附属协和医院老年科,武汉430022 [2]华中科技大学同济医学院附属协和医院心内科

出　　处：《临床心血管病杂志》2018年第8期742-745,共4页Journal of Clinical Cardiology

摘　　要：P2Y12受体抑制剂是急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后双联抗血小板治疗(DAPT)的重要组成部分。本文介绍了P2Y12受体抑制剂在ACS患者PCI术后应用的最新指南推荐,并结合最新临床试验比较了从静脉坎格瑞洛过渡至不同口服P2Y12受体抑制剂方案的优劣,以及PCI术后新型P2Y12受体抑制剂的转换策略,评估了药物基因型检测对P2Y12受体抑制剂方案转换的指导价值。P2Y12 receptor inhibitors are vital components of dual antiplatelet therapy（DAPT）regimen after percutaneous coronary intervention（PCI）in patients with acute coronary syndrome（ACS）.This article introduces the latest guideline recommendations for the application of P2Y12 receptor inhibitors in ACS patients after PCI,and compares different strategies of transition from venous Cangrelor to oral P2Y12 receptor inhibitors,as well as the switching strategy of a new P2Y12 receptor inhibitor after PCI,and evaluates the value of gene detection in P2Y12 receptor inhibitor conversion strategy through several clinical trials.

关 键 词：急性冠状动脉综合征 P2Y12受体抑制剂 经皮冠状动脉介入治疗 抗血小板治疗 基因检测 

分 类 号：R541.4[医药卫生—心血管疾病]